Abstract: Hybrid coronary revascularization (HCR) combines arterial coronary artery bypass surgery (most commonly minimally invasive) and percutaneous coronary intervention in the treatment of a particular subset of multivessel coronary artery disease. It was first introduced in the mid-1990s, and aspired to bring together the "best of both worlds": the excellent patency rates and survival benefits associated with the durable left internal mammary artery graft to the left anterior descending artery alongside the good patency rates of drug-eluting stents, which outlive saphenous vein grafts to non-left anterior descending vessels. Although in theory this is a very attractive revascularization strategy, several years later, only one small randomized controlled trial comparing HCR with coronary artery bypass grafting has recently emerged in the medical literature, raising concerns regarding HCR's role and generalizability. In the current review, we discuss HCR's rationale, the current evidence behind it, its limitations and procedural challenges. 
H ybrid coronary revascularization (HCR) was
first introduced in the mid-1990s (1) as a pioneering treatment approach to multivessel coronary artery disease (CAD), hoping to bring together the "best of both worlds" (2) . HCR aims to reduce surgical trauma while preserving long-term survival and minimizing adverse cardiovascular events.
The hybrid approach includes left internal mammary artery (LIMA) anastomosis to the left anterior descending coronary artery (LAD), typically via a minimally invasive approach, and percutaneous coronary intervention (PCI) for the remaining (non-LAD) lesions. Variations to this schema were discussed in a recent nomenclature paper (3) , including the grafting of multiple coronary vessels (e.g., LIMA to LAD and saphenous graft to diagonal).
THE RATIONALE FOR HCR
The rationale for HCR lies in the well-established survival benefit conferred by LIMA-to-LAD grafts (4) (5) (6) and the use of new stent platforms (7) featuring lower stent restenosis and thrombosis rates compared with venous graft stenosis and occlusion rates, respectively (8) .
THE SURVIVAL BENEFIT OF A SURGICAL LIMA-TO-LAD
GRAFT. A unique conduit, the LIMA powerfully resists thrombosis and atherosclerosis (9) . Consequently, the LIMA-LAD graft is associated with longterm patency rates reaching 98% at 10 years (10, 11) .
Furthermore, a LIMA graft protects the native coronary tree from the deleterious effects of disease pro-
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PCI. Unlike arterial conduits, veins were not designed to bear the load of systemic pressure; hence, venous grafts are more prone to atherosclerotic degeneration and progressive narrowing with high early and long-term failure rates. In the ex vivo PREVENT IV (Vein graft Engineering via Transfection IV) study (12) , angiographic midterm (1 to 1.5 years) saphenous vein graft (SVG) failure, defined as stenosis $75%, stood as high as 46%, whereas reported graft occlusion rates in the literature range from 6.2% to 32% at 1 year (averaging w20%) (13) (14) (15) (16) (17) , 29% at 10 years, and 68% at 15 years (10) post-coronary artery bypass graft surgery (CABG).
Newer drug-eluting stent (DES) platforms with (e.g., everolimus-eluting stents [EES] or zotarolimuseluting stents [ZES] ) or without (bioresorbable polymer-based or polymer-free stents) durable polymers show favorable outcomes, with 1-year target lesion revascularization (TLR) rates as low as 3% to 3.25% (7) and midterm binary ($50%) restenosis rates of 2.3% for EES (8 months) (18) and 3.1% for the amphilimus-eluting, polymer-free stent (6 months) (19) . Even in high-risk patients and complex lesions, ZES and EES maintain very low 1-year TLR rates of 4.4% and 4%, respectively (20) . Thus, PCI and stenting provide strong competition for SVG revascularization because, unlike an LIMA-LAD graft, disease progression in the proximal native coronary segment occurs alongside SVG deterioration.
Moreover, significant angiographic SVG stenosis occurs at least twice as frequently as binary in-stent restenosis using the latest technology platforms.
However, ischemia-driven revascularization rates are considerably higher in stented patients with treated multivessel CAD (21) . Furthermore, even though SVG occlusion occurs at a higher rate compared with stent thrombosis (10) , the clinical consequences of the latter are more dramatic, as it is more frequently associated with major adverse clinical events (MACE) (22) .
PATIENT SELECTION FOR HCR
The role of the heart team in guiding appropriate patient selection for HCR is crucial (23) . In our view, an important anatomical feature favoring HCR should be plaque burden in the proximal LAD well characterized by the SYNTAX (SYNergy Between PCI With TAXUS and Cardiac Surgery) score (24) . The classic indication for HCR is multivessel CAD including: 1) a proximal complex LAD lesion with optimal distal anatomy amenable to LIMA-to-LAD grafting; 2) non-LAD lesions amenable to PCI, in a patient with no contraindications to dual antiplatelet therapy (DAPT); and 3) a high likelihood of achieving "reasonable incomplete revascularization" (25, 26) Association guidelines for CABG state that the "primary purpose of performing HCR is to decrease the morbidity rate of traditional CABG in high-risk patients" (27) . Even in the more recent European Society 
TECHNICAL ISSUES
1-VERSUS 2-STAGED APPROACH. HCR can be performed either simultaneously or as a "2-staged" procedure. The former implies concurrent CABG and PCI in a single operative suite, with PCI following CABG within minutes. In the "2-staged" approach, the optimal order-PCI first versus CABG first-is debated because each approach has advantages and disadvantages (Central Illustration). Currently, decisions should be guided by patient characteristics, operator skill/expertise, and available facilities.
A simultaneous approach is only feasible in hybrid suites featuring state-of-the-art surgical and interventional equipment. Often, CABG is performed first, allowing the interventional cardiologist to study the LIMA-LAD graft before stent implantation. Thus, PCI to high-risk, non-LAD lesions is performed with a protected LAD territory. In case of unsuccessful stent implantation, surgical bailout graft implantation remains an option. Additionally, the simultaneous HCR approach can be cost effective by reducing hospital length of stay (30, 31) , the risk of lesion destabilization, and recurrent hospital admissions between staged procedures. An additional advantage: improved patient satisfaction (30) , as it condenses revascularization into 1 patient encounter (27) .
As for the limitations of this approach, 1 challenge is balancing the need for appropriate antiplatelet therapy, to avoid stent thrombosis, with surgical bleeding risk. Performing the LIMA-LAD anastomosis under DAPT can be difficult, particularly when a minimally invasive approach and video-assisted LIMA take-down are used. Furthermore, the response of DES to protamine administration at the end of CABG has not been fully investigated (32) . When DAPT is not administered to reduce surgical bleeding risk, PCI becomes risky and is not recommended. Another challenging scenario for "1-stop" HCR is the patient with chronic kidney disease, who is exposed in a short period of time to the dual nephrotoxic insult of surgery and contrast media.
When the heart team favors a 2-step procedure, the sequence of PCI and CABG should be guided by clinical presentation and coronary anatomy.
In general, the American College of Cardiology Foundation/American Heart Association guidelines favor performing CABG first (27 Another approach involves a loading dose of clopidogrel at the induction of anesthesia (40) or intraoperatively (35) , because maximal platelet inhibition occurs 4 to 24 h after administration (41, 42) , allowing the surgical step of simultaneous HCR to be performed with acceptable bleeding risk. In some registries, the exact timing and dose of antiplatelet therapy during the "2-step" and simultaneous HCR
are not clearly described, highlighting the need for more robust clinical guidance (43, 44) . Newer antiplatelet agents like prasugrel, ticagrelor, or cangrelor (45) (an investigational agent with rapid onset and reversal) could prove to be safer alternatives for HCR; however, this remains an "evidence-free"
zone.
THE INDIVIDUAL COMPONENTS OF HCR
THE LIMA-LAD ANASTOMOSIS. In most cases, the LIMA-LAD anastomosis can be performed using the minimally invasive approach, which aims to avoid cardiopulmonary bypass and the sternotomy incision.
Minimally invasive direct coronary artery bypass grafting (MIDCAB) is performed on the beating heart through a small, left-sided thoracotomy in the 4th/ 5th interspace via direct visualization. To avoid the significant chest wall manipulation associated with MIDCAB and to improve post-operative pain control, thoracoscopic and robotic techniques have been developed. These include the endoscopic atraumatic coronary artery bypass (Endo-ACAB), which allows thoracoscopic/robotic LIMA identification and mobilization followed by a direct non-rib spreading thoracotomy permitting hand-sewn anastomosis on the beating heart (46) , and the totally endoscopic coronary artery bypass grafting either on-or off-pump, in which the anastomosis is performed intracorporeally using a robot. The latter, although challenging, produces a reported clinical freedom from graft failure as high as 98.6% at 13 months in experienced hands (47) .
WHICH TYPE OF STENT TO IMPLANT?
Without question, modern PCI should be performed with second-or third-generation DES (7, 48, 49) . Irrespective of DES choice, it is essential that DAPT be continued for at least 6 months (50,51). Fully biodegradable DES are an interesting new development (52, 53) , but long-term follow-up data, especially in complex lesions, are needed before we consider them a replacement for current metallic DES.
THE EVIDENCE ON HCR
Since the first report in 1996 (1), there have been multiple publications on single-center experiences
Hybrid Coronary Revascularization Hybrid Coronary Revascularization using HCR, with a cumulative population of >3,000 patients (54), one-third of whom were included in registries published in the last 5 years ( Tables 1 and 2 ). The presentation mode varied across the studies, with ACS prevalence as low as 0% (39) or 13.6% (34) to as high as 74% (40) . In the majority of HCR cases, left ventricular ejection fraction was preserved or, at most, mildly impaired.
Most studies reported an average risk, using additive EuroSCORE, of 3.1 (36) to 6 (56), whereas STS score was as low as 0.018% (34) Tables 1 and 2 . (90%) patients. Binary in-stent restenosis rates were 13%, whereas in-stent thrombosis was observed in 3.7% of patients. In another study of 94 HCR patients with 6-month angiographic follow-up (37), binary instent restenosis was reported in 9% of patients, whereas in-stent thrombosis was seen in 2.2%. These figures concur with those reported from studies using first-generation DES (7).
Follow-up data from HCR registries ( Table 3) demonstrate survival rates of 92.5% (44) to 100% Values are mean AE SD, median (interquartile range), n, or % as indicated. *Statistically significant difference between the 2 groups (p < 0.05). Tables 1, 2 , and 3. Hybrid Coronary Revascularization surgery. However, these results may simply reflect the effect of unadjusted confounders (increased age by w8 years in the HCR group). In contrast, the propensity-matched cohort from Shen et al. (36) showed no difference in MACE rates between HCR and CABG (p ¼ 0.362) in patients with high SYNTAX scores ($30) ( Table 4) . Furthermore, the same study Italy. E-mail: info@emocolumbus.it.
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